PLURISTEM THERAPEUTICS INC - FORM 10-K - EX-32.1 - CERTIFICATION - September 13, 2021

Attached files

file filename
EX-32.2 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2021ex32-2_pluristem.htm
EX-31.2 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2021ex31-2_pluristem.htm
EX-31.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2021ex31-1_pluristem.htm
EX-23.2 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - PLURISTEM THERAPEUTICS INCf10k2021ex23-2_pluristem.htm
EX-23.1 - CONSENT OF KOST FORER GABBAY & KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL - PLURISTEM THERAPEUTICS INCf10k2021ex23-1_pluristem.htm
EX-10.30 - LETTER AGREEMENT BY AND BETWEEN PLURISTEM LTD. AND CHEN FRANCO-YEHUDA, DATED SEP - PLURISTEM THERAPEUTICS INCf10k2021ex10-30_pluristem.htm
EX-10.29 - LETTER AGREEMENT BY AND BETWEEN PLURISTEM LTD. AND YAKY YANAY, DATED SEPTEMBER 1 - PLURISTEM THERAPEUTICS INCf10k2021ex10-29_pluristem.htm
EX-10.28 - LETTER AGREEMENT BY AND BETWEEN PLURISTEM LTD. AND ROSE HIGH TECH LTD., DATED SE - PLURISTEM THERAPEUTICS INCf10k2021ex10-28_pluristem.htm
EX-10.20 - FORM OF RESTRICTED STOCK UNIT AGREEMENT (EMPLOYEES) UNDER THE 2019 EQUITY COMPEN - PLURISTEM THERAPEUTICS INCf10k2021ex10-20_pluristem.htm
EX-10.19 - FORM OF RESTRICTED SHARE UNIT AGREEMENT (ISRAELI DIRECTORS AND OFFICERS) UNDER T - PLURISTEM THERAPEUTICS INCf10k2021ex10-19_pluristem.htm
EX-10.18 - FORM OF RESTRICTED SHARE UNIT AGREEMENT UNDER THE 2019 EQUITY COMPENSATION PLAN - PLURISTEM THERAPEUTICS INCf10k2021ex10-18_pluristem.htm
10-K - ANNUAL REPORT - PLURISTEM THERAPEUTICS INCf10k2021_pluristemtherap.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

 

In connection with the Annual Report on Form 10-K of Pluristem Therapeutics Inc. (the “Company”) for the period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, as the Chief Executive Officer and President of the Company, hereby certifies pursuant

to 18 U.S.C. Section 1350 that, to my knowledge:

 

1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Dated: September 13, 2021

 

/s/ Yaky Yanay  
Yaky Yanay  
Chief Executive Officer, President  

 

PLURISTEM THERAPEUTICS INC Reports